Last reviewed · How we verify
NCT07318818
A Clinical Trial of P134 Cells in Recurrent Glioblastoma
Phase 1, PHASE2 trial testing P134 cell injection in Recurrent Glioblastoma IDH Wildtype in 26 participants. Currently enrolling.
29 February 2028
Quick facts
| Lead sponsor | Tasly Pharmaceutical Group Co., Ltd |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 26 |
| Start date | 5 January 2026 |
| Primary completion | 29 February 2028 |
| Estimated completion | 31 August 2028 |
| Sites | 1 location across China |
Drugs / interventions tested
- P134 cell injection — full drug profile →
Conditions studied
- Recurrent Glioblastoma IDH Wildtype — all drugs for Recurrent Glioblastoma IDH Wildtype →
Sponsor
Tasly Pharmaceutical Group Co., Ltd — full company profile →
Who can join
Adults 18 to 70, any sex, with Recurrent Glioblastoma IDH Wildtype. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is an open-label, single-arm, dose-escalation and expansion Phase 1/2 clinical trial designed to evaluate the safety, tolerability and efficacy of P134 cells in patients with recurrent glioblastoma, to explore the maximum tolerated dose (MTD)and recommended Phase 2 dose (RP2D), and to characterize the cytokinetic profile of CAR-T cells in the cerebrospinal fluid of patients. Eligible participants are adults diagnosed with recurrent or progressive glioblastoma who are confirmed as grade 4 glioblastoma (IDH wild-type) by histopathology or molecular pathology. P134 cells are CD44/CD133 dual-targeting CAR-T cells developed by the research team led by Academician Jiang Tao and Professor Zhang Wei from the Beijing Neurosurgical Institute and the Department of Neurosurgery, Beijing Tiantan Hospital. This study is spearheaded by Professor Zhang Wei of the Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, China, with scientific oversight and guidance provided by Academician Jiang Tao of the Chinese Academy of Engineering.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07318818
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Recurrent Glioblastoma IDH Wildtype
Currently open trials in the same condition.
- NCT06455605 — D2C7-IT + 2141-V11 Combination Post-resection in rGBM · Phase 1 · recruiting
Other Tasly Pharmaceutical Group Co., Ltd trials
Trials by the same sponsor.
- NCT07269769 — A Clinical Trial Evaluating the Efficacy and Safety of Sanhuang Jingshiming Pills in the Treatment of nAMD · Phase 3 · not yet recruiting
- NCT07485595 — A Study of the Effectiveness and Safety of JS1-1-01 Tablet in Patients With Moderate to Severe Depression · Phase 2, PHASE3 · not yet recruiting
- NCT07514065 — TSL2109 Capsules in Advanced Solid Tumor Patients: Safety, Tolerability, PK and Preliminary Efficacy · Phase 1 · recruiting
- NCT07265349 — A Phase I/II Clinical Trial of Intramyocardial Injection of HucMSCs for the Treatment of Chronic Heart Failure · Phase 1, PHASE2 · recruiting
- NCT06773117 — Phase III Trial of Susu Zhike Granules in Children With Cold-cough Syndrome for Acute Cough Treatment · Phase 3 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07318818 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Tasly Pharmaceutical Group Co., Ltd
- Last refreshed: 18 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07318818.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing